You are here

  • Home
  • Archive
  • Volume 109, Issue 23
  • Correspondence on “Beta-blockers and renin-angiotensin system inhibitors for Takotsubo syndrome recurrence: a network meta-analysis” by Santoro et al

Article Text

Article menu
Download PDFPDF
Correspondence
Correspondence on “Beta-blockers and renin-angiotensin system inhibitors for Takotsubo syndrome recurrence: a network meta-analysis” by Santoro et al
  1. John E Madias
  1. Cardiology, Icahn School of Medicine at Mount Sinai/Cardiology Division, Elmhurst Hospital Center, Elmhurst, New York, USA
  1. Correspondence to Professor John E Madias, Cardiology, Icahn School of Medicine at Mount Sinai/Cardiology Division, Elmhurst Hospital Center, Elmhurst, NY 11373, USA; madiasj{at}nychhc.org

https://doi.org/10.1136/heartjnl-2023-323430

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Santoro et al, 1 in their carefully designed and implemented meta-analysis, have concluded that beta-blockers (BB) and renin–angiotensin system inhibitors (RASI), administered after an index episode of Takotsubo syndrome (TTS), are not protective of recurrence. Scrutiny of the ‘limitations’ section of their paper reveals that there are many drawbacks in implementing meta-analyses of existing data from the literature, suggesting that we should resort to large multicentre registries and randomised controlled trials to resolve the conundrum whether such therapy(ies) could prevent TTS recurrence. This author believes that exploration of whether BB and/or RASI could …

    View Full Text

    Footnotes

    • Contributors As a sole author of this work, I have contributed to its conception, literature search, writing, editing and submission.

    • Funding The author has not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles